Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) EBITDA (2017 - 2025)

Historic EBITDA for CollPlant Biotechnologies (CLGN) over the last 9 years, with Q3 2025 value amounting to -$3.5 million.

  • CollPlant Biotechnologies' EBITDA rose 2278.73% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 20342.86%. This contributed to the annual value of -$17.3 million for FY2024, which is 12964.59% down from last year.
  • According to the latest figures from Q3 2025, CollPlant Biotechnologies' EBITDA is -$3.5 million, which was up 2278.73% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, CollPlant Biotechnologies' EBITDA registered a high of $10.0 million during Q1 2021, and its lowest value of -$5.1 million during Q4 2023.
  • Moreover, its 5-year median value for EBITDA was -$3.1 million (2021), whereas its average is -$443789.5.
  • The largest annual percentage gain for CollPlant Biotechnologies' EBITDA in the last 5 years was 68734.62% (2021), contrasted with its biggest fall of 10042.15% (2021).
  • CollPlant Biotechnologies' EBITDA (Quarter) stood at -$3.8 million in 2021, then fell by 22.92% to -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then rose by 21.59% to -$4.0 million in 2024, then grew by 11.75% to -$3.5 million in 2025.
  • Its EBITDA was -$3.5 million in Q3 2025, compared to $3.2 million in Q2 2025 and $1.6 million in Q1 2025.